New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma
Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | Russian |
| Julkaistu: |
IRBIS LLC
2023-07-01
|
| Sarja: | Фармакоэкономика |
| Aiheet: | |
| Linkit: | https://www.pharmacoeconomics.ru/jour/article/view/807 |